- Home
- / AnaptysBio
AnaptysBio
Stock Price
$30.8
2024-10-29
Market Capitalization
$930.2 M
2024-10-29
Revenue
$234.6 M
FY, 2025
AnaptysBio Summary
Company Summary
- Overview
- AnaptysBio is a biotechnology company developing immunology therapeutic product candidates. It focuses on immune control mechanisms applicable to inflammation and immuno-oncology indications. The company offers ANB019, ANB030, and ANB032 antibody programs to address inflammatory disorders.
- Type
- Public
- Status
- Active
- Founded
- 2005
- HQ
- San Diego, CA, US | view all locations
- Website
- https://www.anaptysbio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Beth Mueller, Senior Vice President, Human Resources
Dennis Mulroy, Chief Financial Officer
John Schmid, Director
LocationsView all
2 locations detected
San Diego, CA HQ
United States
10770 Wateridge Cir Ste. 210
San Diego, CA
United States
10421 Pacific Center Ct #200
AnaptysBio Financials
Summary Financials
- Revenue (Q1, 2026)
- $25.6M
- Net income (Q1, 2026)
- ($52.9M)
- Cash (Q1, 2026)
- $248.5M
- EBIT (Q1, 2026)
- ($34.6M)
- Enterprise value
- $695.3M